Skip to content

Feasibility of CGM Use in Hospitalized Youth

Feasibility of Continuous Glucose Monitor Use In Hospitalized Youth

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06143202
Enrollment
120
Registered
2023-11-22
Start date
2025-07-15
Completion date
2027-02-14
Last updated
2026-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperglycemia

Keywords

Hyperglycemia, Continuous glucose monitors, Pediatrics, Hospital, Diabetes

Brief summary

This study is assessing the feasibility of a continuous glucose monitor during hospital admissions in youth and young adults with hyperglycemia due to diabetes or other underlying conditions that requires frequent glucose monitoring, through patient/family and nursing staff feedback on their perspectives and usability of the system in the hospital will be assessed through surveys. In addition, retrospective glycemic comparisons between CGM data and POC will be conducted.

Detailed description

Youth and young adult patients admitted to the hospital for any reason, but require glucose monitoring during the hospitalization will be enrolled in this study. Participant diagnosis can include type 1 diabetes, type 2 diabetes, medication-induced diabetes, cystic fibrosis-related diabetes, or other causes of hyperglycemia that it has been determined by the hospital team requires frequent glucose monitoring, with or without insulin management. Enrolled participants will wear a blinded continuous glucose monitor for up to 28 days (2 sensors) or until the end of their hospitalization. In addition, enrolled participants will complete a survey to assess their perspectives on the CGM wear experience and interest in future CGM use during hospitalizations. Nursing staff of the enrolled participant will also be invited to complete a survey regarding their perspectives of CGM use in the hospital setting.

Interventions

DEVICEFreestyle Libre 3 Continuous Glucose Monitor

Youth and young adult participants will wear a blinded Freestyle Libre 3 CGM. Data will not be available, and therefore the device will not be used to modify medical management.

Sponsors

University of Colorado, Denver
Lead SponsorOTHER
University of California, San Francisco
CollaboratorOTHER
Stanford University
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 26 Years
Healthy volunteers
No

Inclusion criteria

1. Participants will be 2 to less than 26 years of age at the time of enrollment. 2. Participants will have a diagnosis of type 1 diabetes, type 2 diabetes, diabetes/hyperglycemia due to an underlying condition (such as in cystic fibrosis, monogenic diabetes), or medication induced diabetes/hyperglycemia (such as steroid-induced hyperglycemia or PEG-asparaginase induced hyperglycemia) and would benefit clinically from close glucose monitoring during hospitalization due to fluctuations in blood glucose values. 3. Participant is expected to be in the hospital for longer than 12 hours after study enrollment with a goal of 36 hours or more as determined by study investigator or trained staff. 4. Participant is willing to wear the continuous glucose monitor for the duration of the hospital admission or the lifespan of a continuous glucose monitor (7-14 days).

Exclusion criteria

1. Has had a history of a significant skin reaction to the adhesives of a continuous glucose monitor in the past or concerns that one may occur due to underlying skin conditions (ie severe eczema, uncontrolled psoriasis, etc). 2. Planned MRI or surgery during the study device use (can be enrolled pre or post procedure if sufficient time for sensor wear as determined by investigator \[i.e. 24-48 before planned procedure\]). 3. Admission to inpatient psychiatry. 4. Pregnancy. 5. Currently using hydroxyurea. 6. A condition that the investigator determines would prevent the patient from participation.

Design outcomes

Primary

MeasureTime frameDescription
Retrospective glycemic CGM and point of care comparisonDuration of study, approximately 1 year from study startGlycemic data related to time in range, time hypoglycemic, time hyperglycemic and the time of first onset of hypoglycemia and hyperglycemia will be obtained by both CGM and point of care glucose values.

Secondary

MeasureTime frameDescription
Nursing staff perspectives of CGM use in the hospitalDuration of study, approximately to 1 year from study startSurveys will be provided to the nursing staff associated with an enrolled patient participant to obtain qualitative perspectives on the usability of CGMs in the hospital setting
Patient/Family perspectives of CGM use in the hospitalDuration of study, approximately 1 year from study startSurveys will be completed by patients/family to evaluate their experience with sensor wear in the hospital, sensor insertion, and goals for glycemic monitoring while in the hospital.
Feasibility of CGM use through assessment of discontinuation and data lossDuration of study, approximately 1 year from study startIdentify the frequency and causes of sensor discontinuation as well as information on sensor data loss.
Health economics dataDuration of study, approximately 1 year from study startPilot analysis of health economics data from costs related to glycemic monitoring during the hospitalization.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026